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Abstract 
The inflammatory pathways involved in asthma are more complex than the sole Th2-mediated eosinophilic 
airway inflammation. Different phenotypes of asthma have been recently highlighted and are probably underlied 
by different immunological profiles. The aim of the study was to assess cytokine production from sputum cells 
in eosinophilic versus non-eosinophilic asthmatics. Induced sputum was obtained from 48 consecutive stable 
mild to moderate asthmatics (20 eosinophilic asthmatics, 28 non-eosinophilic asthmatics) and 31 healthy 
subjects. Cytokine released from sputum cells were measured by a home-made two-step sandwich immunoassay. 
Cytokines investigated were interleukin (IL)-4, IL-6, IL-10, tumour necrosis factor (TNF)-α and interferon 
(IFN)-γ. Sputum cells from eosinophilic asthmatics produced more IL-4 than those from both healthy subjects 
(P<0.05) and non-eosinophilic asthmatics (P < 0.05). Conversely, sputum cells from eosinophilic asthma were 
found to release lower amounts of TNF-α than those from healthy subjects (P < 0.05). The group of non-
eosinophilic asthmatics did not distinguish from healthy subjects with respect to any cytokines measured. 
Sputum cells from asthmatics exhibiting eosinophilic airway inflammation release more IL-4 and less TNF-α 
than those of healthy subjects. By contrast, non-eosinophilic asthmatics did not distinguish from healthy subjects 
by abnormal cytokine release from their sputum cells. 
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INTRODUCTION 
Emphasis has been recently placed on the heterogeneity of airways inflammation in asthma [1]. Although 
airways eosinophilia governed by Th2 cytokines is regarded as a prominent feature of asthma [2], it has become 
clear that a substantial part of asthmatics may not exhibit raised number of eosinophils in airways lumen [3] or 
bronchial walls [4]. The distinction between eosinophilic and non-eosinophilic asthma may not be purely 
academic as it might be relevant to the response to inhaled corticoids [5] and the propensity to develop asthma 
exacerbations [6]. 
Immunological studies comparing eosinophilic versus non-eosinophilic asthma are still sparse and potential 
immune mechanisms involved in non-eosinophilic asthma still largely unknown. Induced sputum was shown to 
be a useful technique to sample airways cells. Thanks to its relative non-invasiveness and good cell count 
reproducibility, induced sputum has allowed the definition of normal cell counts derived from large samples of 
healthy subjects [7,8]. From these studies and our own data it appeared that a sputum percentage of eosinophils 
greater than 2.2% could be considered as abnormal. 
We have demonstrated previously that sputum cells spontaneously release cytokines when cultured ex vivo and 
that this release was modulated by allergen exposure in sensitized subjects [9]. In order to delineate the 
immunological basis of asthmatic phenotypes, we have compared the cytokine production from sputum cells in 
eosinophilic versus non-eosinophilic stable asthmatics. Interleukin (IL)-4 and interferon (IFN)-γ were chosen as 
markers of Th2/Th1 balance [10], tumour necrosis factor (TNF)-α and IL-10 as pro- and anti-inflammatory 
cytokines, respectively [11,12] and IL-6 as a cytokine released in inflammatory state that may stimulate humoral 
immunity [13]. 
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MATERIALS AND METHODS 
Study design and subject characteristics 
We recruited 48 consecutive asthmatics from our asthma clinic whose demographic, functional and treatment 
characteristics are given in Table 1. Asthma was defined by the presence of recurrent symptoms of 
breathlessness, cough or wheezing associated with bronchial hyperresponsiveness. The demonstration of 
bronchial hyperresponsiveness was based on either a positive methacholine challenge when baseline forced 
expiratory volume in 1 s ( FEV1) was greater than 70% predicted or a reversibility of FEV1 greater than 12% 
after 400 µg inhaled salbutamol when baseline FEV1 was lower than 80% predicted. A positive methacholine 
challenge was defined as a provocative concentration of methacholine causing a fall in FEV1 of 20% from 
baseline (PC20M) ≤ than 16 mg/ml. Methacholine challenges were performed according to a slightly modified 
Cockroft's method, as described previously [14]. Atopy was defined as a positive skin-prick test reaction (wheal 
≥ 3 mm compared to control) to common aeroallergens of our area (house dust mites, cat and dog dander, grass, 
tree and weed pollens, moulds). All asthmatics were in stable condition at the time sputum induction in that none 
were in a situation to require systemic corticoids or to need transfer to an emergency department. The study was 
approved by our local ethical committee and each subjects gave its oral informed consent. 
Sputum induction and processing 
After premedication of the subjects with a 400 µg inhaled salbutamol (pMDI + spacer), sputum was induced by 
inhalation of an hypertonic saline (NaCl 4.5%) combined with additional salbutamol [15] delivered by an 
ultrasonic nebulizer (Ultra-Neb 2000, De Vilbiss) with an output set at 0.9 ml/min. Each subject inhaled the 
aerosol for three consecutive periods of 5 min for a total time of 15 min. For safety reasons, FEV1 was monitored 
every 5 min and the induction stopped when FEV1 fell by more than 20% from post-bronchodilation value. 
The whole sputum was collected in a plastic container, weighed and homogenized by adding three volumes of 
phosphate-buffered saline (PBS), vortexed for 30 s and centrifuged at 800 g for 10 min at 4°C. Supernatant was 
separated from cell pellet which was resuspended in PBS without Ca2+ and Mg2+ and used to perform squamous 
and total cell counts with a manual haemocytometer. Cell viability was checked by trypan blue exclusion. The 
differential performed on cytospins stained with Diff-Quick. According to our own laboratory reference values 
obtained on a large sample of healthy non-atopic subjects (n = 62, mean age 34) sputum eosinophil counts 
greater than 2.2% (90th percentile) and neutrophil counts greater than 57.6% (90th percentile) were considered 
as abnormally high. 
Sputum cell culture and cytokine assays 
Cytokines (IL-4, IL-6, IL-10, TNF-α, IFN-γ) were measured by a two-step sandwich type immunoassay. The 
antibodies and standards were purchased from Biosource (Cytosets, Biosource, Fleurus, Belgium). Fifty µl from 
standards or sputum cell suspension (2 × 106 non-squamous cells) was incubated at 37°C with 200 µl RPMI-
1640 supplemented with 100 U penicillin/ml and 100 µg streptomycin/ml (Cambrex, Verviers, Belgium) and 2% 
of inactivated fetal calf serum (Cambrex) in apyrogen microwells (Nunc Maxisorp, VWR, Belgium), which were 
coated previously with specific antibodies directed towards the chosen cytokines. After 24 h cell culture viability 
was checked by trypan blue and was usually > 80%. The wells were then washed and 150 µl of a solution 
containing biotinylated detection antibodies (0.23 µg/ml) specific to the cytokines was added for 2 h at room 
temperature. Then, wells were washed again and filled with a solution containing streptavidin horseradish 
peroxidase (HRP) for 45 min at room temperature. After washing, 100 µl tetramethylbenzidine (TMB) 
chromogen solution was added as a chromogen solution for 20 min in the dark. The reaction was stopped by 
adding 50 µl H2SO4 1 M. The amount of substrate converted to products was thereafter detected as optical 
densities (OD) at 450 nm in an enzyme-linked immunosorbent assay (ELISA) reader (Multiscan Ascent, Thermo 
Labsystems, Helsinki, Finland). The sensitivities of our assays were 6 pg/ ml for IL-4, 6 pg/ml for IL-6, 4 pg/ml 
for IL-10, 6 pg/ml for TNF-α and 7 pg/ml for IFN-γ. 
Statistical analyses 
Results were expressed as median (range). Comparisons between the three groups were performed by Kruskall-
Wallis test followed, when significance arose, by Dunn's test for pairwise comparisons. Correlations were tested 
by using Spearman's coefficient of correlation. P-values less than 0.05 were considered as statistically 
significant. 
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Table 1. Subject characteristics. 
 Eosinophilic asthma 
n = 20 
Non-eosinophilic asthma  
n = 28 
Healthy subjects        
n = 31 
Age (years) 43.2 ± 16.8 39.7 ± 17.8 39.8 ± 11.7 
Sex (M,F) 11/9 13/12 22/9 
Skin-prick + 13 18 0 
FEV1 (L) 3.225 ± 1.117 3.098 ± 0.966 4.066 ± 0.949 
FEV1 (%) 87.4 ± 20.9 90.2 ± 15.5 110.8 ± 17 
FVC (L) 4.093 ± 1.517 3.744 ± 1.306 4.983 ± 1.208 
FVC (%) 93 ± 24.9 94.6 ± 16.8 110 ± 18 
FEV1/FVC 73.3 ± 9.3 82.4 ± 16.6 85.8 ± 13.7 
PC20M (mg/ml) 2.02 (0.37-14) 1.72 (0.35-12) > 16 
Smoking habits 13 NS/3 ES/4 S 15 NS/6 ES/7 S 19 NS/5 ES/7S 
IgE (KU/ml) 736 (64-1044) 478 (16.4-1020) 29 (5-90) 
Treatment:    
   No ICS 11 13 31 
   ICS 9 15 0 
Results are expressed as mean ± s.d. except PC20M which is expressed as geometric mean (range). NS: non smoker, ES: ex smoker, CS: 
current smoker, ICS: inhaled corticosteroids. 
 
RESULTS 
Sputum cell counts in eosinophilic versus non-eosinophilic asthma are given in Table 2. The two groups of 
asthmatics did not differentiate between each other or with healthy subjects with respect to any cell type except 
eosinophil count (Table 2). In particular, the number of patients exhibiting an abnormally high neutrophil count 
(> 58%) was not different in eosinophilic (five of 20; 25%) and in non-eosinophilic asthmatics (eight of 28; 
28%). 
The results regarding the cytokines released from sputum cell culture are given in Table 3. Eosinophilic 
asthmatics displayed a raised production of IL-4 when compared to both non-eosinophilic asthmatics and healthy 
subjects (Fig. 1). By contrast, the release of TNF-α was lower in eosinophilic asthmatics when compared to 
healthy subjects (Fig. 2). There was no difference between the groups regarding IL-6, IL-10 and IFN-γ 
production (Fig. 3). 
With regard to the amount of TNF-α produced [2703 pg/ ml (129-4243) versus 2232 pg/ml (0-6771), 
respectively, P > 0.05], those subjects who released IL-4 were not different from the non-IL-4 releasers. 
When analysing the data according to the atopic status, no difference in cytokine production could be detected 
between atopic and non-atopic asthmatics (P > 0.05 for each cytokine). In the same line, total serum IgE levels 
failed to relate significantly to the production of any cytokine considered (P > 0.05 for each cytokine). 
In each group of asthmatics (eosinophilic and non-eosinophilic), those taking regular inhaled steroids as 
maintenance treatment did not differ from their steroid naive counterparts with respect to any cytokine 
considered (P >0.05). 
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Table 2. Sputum cell count. 
 Eosinophilic asthmatics Non-eosinophilic asthmatics Healthy subjects 
Total cells  
× 106/ml 
 
0.75 (0.12-0.5) 
 
0.7 (0.01-22.6) 
 
0.53 (0.05-2.4) 
Cell viability 
% 
 
51 (29-98) 
 
70.5 (37-98) 
 
63 (36-100) 
Squamous 
% 
 
17 (0-52) 
 
20.5 (0-55) 
 
18 (0-61) 
Macrohages  
%  
× 106/g 
 
30.5 (3.2-77)  
0.18 (0.03-2.48) 
 
44.8 (0.8-91.2)  
0.24 (0.01-2.62) 
 
42 (1.6-96)  
0.29 (0.01-1.8) 
Lymphocytes 
% 
x 106/g 
 
1.3 (0-11.4)  
0.015 (0-0.57) 
 
0.8 (0-14.4)  
0.01 (0-0.34) 
 
2.2 (0-10)  
0.01 (0-0.24) 
Neutrophils  
%  
× 106/g 
 
23.2 (0-82.6)  
0.18 (0-2.3) 
 
40 (0.8-95.9)   
0.2 (0-21.7) 
 
30 (0-87)  
0.25 (0.01-1.04) 
Eosinophils  
%  
× 106/g 
 
11 (3.4-94)   
0.095 (0.01-3.9) 
 
0.4 (0-2)  
  0.01 (0-0.41) 
 
0.2 (0-3.6)   
0.01 (0-0.04) 
Epithelial cells  
%  
× 106/g 
 
7.8 (0.2-28.2)  
0.05 (0-0.53) 
 
4.2 (0.2-61.6)  
0.03 (0-0.26) 
 
9.8 (0.4-66.4)  
0.06 (0-0.35) 
Results are expressed as median (range). 
 
Table 3. Cytokine production from sputum cells. 
Cytokine (pg/ml) Eosinophilic asthmatics Non-eosinophilic asthmatics Healthy subjects 
IL-4 1.6 (0-1183)* 0 (0-51) 0 (0-0.25) 
IL-6 35 (0-1370) 21 (0-1281) 29.2 (0-807) 
IL-10 37 (12-870) 26.4 (0-2000) 43 (1-253) 
IFN-γ 0 (0-1000) 0 (0-94) 0 (0-3420) 
TNF-α 1139 (130-4000)† 2107 (0-6771) 2290 (140-389) 
Results are expressed as median (range). *P < 0.01 versus non-eosinophilic asthmatics and versus healthy subjects. †P < 0.05 versus healthy 
subjects. IL: interleukin; IFN: interferon; TNF: tumour necrosis factor. 
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Fig. 1. Sputum cell production of interleukin (IL)-4 in non-eosinophilic asthmatics (filled square), eosinophilic 
asthmatics (open triangle) and healthy subjects (filled circle). 
 
 
 
Fig. 2. Sputum cell production of tumour necrosis factor (TNF)-α in non-eosinophilic asthmatics (filled square), 
eosinophilic asthmatics (open triangle) and healthy subjects (filled circle). 
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Fig. 3. Sputum cell production of interleukin (IL)-6 (upper panel), IL-10 (middle panel) and interferon (IFN)-γ 
(lower panel) in non-eosinophilic asthmatics (filled square), eosinophilic asthmatics (open triangle) and healthy 
subjects (filled circle). 
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DISCUSSION 
Our study shows that sputum cells from eosinophilic asthmatics produced more IL-4 than those from both 
healthy subjects and non-eosinophilic asthmatics. Conversely, sputum cells from eosinophilic asthma were found 
to release lower amounts of TNF-α than those from healthy subjects. The group of non-eosinophilic asthmatics 
did not distinguish from healthy subjects with respect to any cytokines measured. Our finding of a raised 
production of IL-4 in eosinophilic asthmatics is in keeping with the observation that a prominent Th2 cytokine 
profile is associated with eosinophilic inflammation in asthmatic airways [16]. One way through which local 
release of IL-4 into the airways may favour the recruitment of eosinophils is the induction of eotaxin release 
from epithelial cells [17]. As we have used the global sputum cell population, we can only speculate about the 
cell type involved in cytokine production. The main source of IL-4 in asthma has been thought to be CD4 T 
lymphocytes [18]. Although found to be increased in sputum from asthmatics, CD4 lymphocytes represent only 
a minority of cells recovered from sputum [19]. One alternative explanation for our observation might be the fact 
that eosinophils themselves produce most of the IL-4 measured from the cell culture. If that were true, high local 
IL-4 production would be then considered as a key event in the perpetuation of local eosinophilic inflammation. 
Supporting this view are the facts that eosinophils from peripheral human blood were shown to synthetize and 
release IL-4 [20] and that IL-4 was found to be localized within eosinophils contained in the bronchial mucosa of 
asthmatics [21]. 
So far, IL-4 has been considered mainly as a pivotal cytokine to drive IgE production from B cells [22]. 
Interestingly, in our study the raised IL-4 production did not relate to atopic status nor to total serum IgE levels 
in asthmatics. The rise in IL-4 production in non-atopic asthmatics fits with data reported by Humbert et al. [23]. 
Of course, it could be argued that the production of IL-4 in the airways is mainly relevant to the local production 
of IgE, which is not necessarily reflected by serum levels [24]. 
One surprising observation of our study is the lower TNF-α production in the group of eosinophilic asthma. 
Macrophages certainly represent an important source of TNF-α production in the airways [11]. However, 
although slightly reduced in eosinophilic asthma, the percentage of macrophages did not differ significantly 
between the groups. Therefore it is unlikely that the low TNF-α release can be accounted for only by the sole 
reduced proportion of macrophages in the cell culture. An additional explanation might be that high local release 
of IL-4 reduces the production of TNF-α from macrophages [25]. However, the fact that those who produced IL-
4, as opposed to the non-producers, failed to show reduced production of TNF-α indicates that the mechanisms 
regulating TNF-α production are more complex and depend on other factors than IL-4. Monoclonal antibodies 
towards TNF-α have been developed recently and proved to be efficient in rheumatoid arthritis [26] and Crohn's 
disease [27] and some trials are currently ongoing in asthma. Our results suggest that a group of mild to 
moderate eosinophilic asthma might not be the best target for using anti-TNF-α in asthma. 
Somewhat unexpectedly, we did not find increased IL-6 production in asthma. IL-6 is considered to be a non-
specific inflammatory cytokine as it is released in several types of inflammation. Circulating levels of this 
cytokine were shown to rise during an asthma exacerbation [28] and secretion of IL-6 from blood leucocytes in 
response to lipopolysaccharide were found to be increased in both atopic and no-atopic asthma when compared 
to healthy subjects [29]. From our data, IL-6, in contrast to IL-4, did not appear to be related closely to 
eosinophilic inflammation. 
Recent interest has emerged for IL-10, a cytokine produced by T regulator lymphocyte and thought to curb 
inflammation and to protect against diseases such as asthma [12]. Sputum levels of IL-10 were reported to be 
lower in asthma when compared to healthy subjects [30]. No significant difference regarding IL-10 could be 
observed between the different groups in our study, even when the levels of IL-10 were slightly lower in 
asthmatics compared to healthy subjects. As far IFN-γ is concerned, the cytokine was poorly detectable in our 
model and not different between the groups. 
Although sharing similar clinical characteristics with its eosinophilic counterpart, the group of non-eosinophilic 
asthmatic patients did not distinguish from that of healthy subjects regarding cytokine production, nor with 
regard to sputum cell counts. In particular, in our series only eight of 28 patients had abnormally high sputum 
neutrophil counts (> 58% according to our laboratory reference values in healthy subjects). This indicates that, in 
the majority of non-eosinophilic patients, mild to moderate asthma cannot be considered as neutrophilic. 
Therefore our data emphasize that the clinical asthma phenotype defined by symptoms and bronchial 
hyperresponsiveness may exist without marked airway leucocyte infiltration and disturbed cytokine release from 
cells contained in airway secretions. Recent data have highlighted the importance of remodelling of extracellular 
matrix and airway smooth muscle in determining the asthmatic phenotype [31]. In the absence of a good soluble 
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biochemical marker, these aspects of asthma may not be identified by the analysis of sputum itself. 
We conclude that eosinophilic asthmatics exhibit an overproduction of IL-4 together with a reduced production 
of TNF-α from their sputum cells when compared to healthy subjects. In contrast, their non-eosinophilic 
counterparts did not differentiate from healthy subjects with respect to sputum cell counts and ex vivo cytokine 
release. 
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